Highest-materiality recent filing
Envoy Medical receives Nasdaq extension to November 16, 2026 to cure bid price deficiency
Company received Nasdaq notice granting additional 180-day period until November 16, 2026 to meet $1.00 minimum bid price.
Envoy Medical completes pivotal trial enrollment for fully implanted cochlear implant; raises $30M
Completed enrollment of 56 patients in U.S. pivotal trial for Acclaim cochlear implant; first three patients reach 12-month endpoint.
FY2025 net revenue $241k, up from $225k (YoY +$16k). No EPS given.
Envoy Medical regains compliance with Nasdaq listing requirement after MVLS deficiency
Received Nasdaq letter confirming compliance with Listing Rule 5550(b)(2) after MVLS fell below $35M.
Envoy Medical closes $30.0M public offering; milestone-linked warrants could add $48.0M
Gross proceeds $30.0M from 75M shares/pre-funded warrants at $0.40/unit; up to $48M additional if milestone warrants exercised for cash.
Envoy Medical receives Nasdaq deficiency notice for minimum bid price non-compliance
Nasdaq notified Envoy Medical on Nov 19, 2025 that common stock failed minimum $1.00 bid price for 30 consecutive business days.
Envoy Medical eliminates $32M debt, gets FDA approval to expand cochlear implant trial
Extinguished over $32 million in debt, strengthening balance sheet without equity issuance.
Envoy Medical gets Nasdaq extension until Feb 23, 2026 to meet listing requirement
Nasdaq panel grants exception until Feb 23, 2026 to comply with $35M market value listing rule.
Envoy Medical announces up to $16M registered direct offering and warrant sale
Offering includes 3,007,524 shares at $1.33/share for ~$4M upfront; warrants for 9,022,572 shares at $1.33.
Envoy Medical gets FDA nod to expand pivotal Acclaim cochlear implant trial to final stage
FDA approved expansion based on 3-month data from first 10 patients; no SAEs or UADEs reported.
Envoy Medical enters voting/warrant extension deal with 47.8% holder Glen Taylor
Taylor Parties agree to vote shares in favor of Nasdaq listing proposals through Dec 31, 2028.
Envoy Medical faces Nasdaq delisting for failing MVLS requirement
Nasdaq notified Envoy Medical on August 26, 2025 that it failed to regain compliance with the $35M MVLS requirement within a 180-day cure period.
Envoy Medical extinguishes $32M debt for $100k; Glen Taylor resigns from board
Paid $100,000 to satisfy $32,011,552 in principal and accrued interest on three promissory notes held by GAT Funding (Glen Taylor).
Envoy Medical reports Q2 clinical progress, cash $5.3M; CPT codes for Esteem device effective July 1
All 10 Acclaim cochlear implant trial participants activated; no serious adverse events at one-month follow-up.
Envoy Medical draws remaining $5M from GAT Funding; issues warrant for 750K shares at $1.48
Drew $5M remaining principal under March 2025 note from GAT Funding, controlled by board member Glen Taylor.
Envoy Medical CFO David R. Wells departs; CEO Lucas becomes interim CFO
David R. Wells ceased as CFO effective May 16, 2025, without cause.
Envoy Medical Q1 revenue down $13k; enrolls 10 in pivotal CI trial; secures $10M funding
Net revenues decreased $13k YoY to an undisclosed amount; cash balance $5.3M as of March 31, 2025.
Envoy Medical FY2024 revenue down $91K; clinical trial enrollment advances
Net revenues decreased $91K YoY; cash and equivalents were $5.5M as of Dec 31, 2024.
Envoy Medical obtains $10M promissory note from largest shareholder Glen Taylor
Initial $5M funded on March 11, 2025; up to $10M available in $2.5M tranches over 2 years.
Envoy Medical receives Nasdaq deficiency notice for low market value of listed securities
Nasdaq notified Envoy Medical on Feb 25, 2025 that market value of listed securities fell below $35M for 31 consecutive business days.
Envoy Medical enters $15M at-the-market equity offering with Roth Capital
ATM agreement with Roth Capital Partners for up to $15M of Class A common stock.
Sponsor Anzu waives $3,733,333 in accrued dividends on Series A Preferred Stock.
Envoy Medical draws $5M from GAT Funding note, issues warrant for 500k shares
Drew $5M under promissory note from GAT Funding (entity controlled by board member Glen Taylor); total principal now $10M.
Envoy Medical Q3 revenue falls to $56K; FDA OKs pivotal trial for Acclaim CI
Net revenues $56K for Q3 2024, down 30% from $80K in Q3 2023; nine-month revenues $183K, down 17%.
Envoy Medical Q2 revenue $68k, cash $1.7M; Acclaim CI pivotal trial goal by end-2024
Revenue $68k (Q2 2024) vs $63k prior year; revenue from two Esteem units offset by battery sales decline.
Senate bill S.4829 (Hearing Device Coverage Clarification Act) introduced July 29 by Klobuchar (D-MN) and Lankford (R-OK).
Envoy Medical draws $2.5M under note from GAT Funding; issues warrant for 250K shares
Drew $2.5M from GAT Funding LLC (controlled by director Glen Taylor); aggregate $7.5M of $10M max.
Envoy Medical Q1 revenue $59K, down from $78K; draws $5M from $10M Glen Taylor loan
Revenue $59K for Q1 2024 vs $78K in Q1 2023; decrease due to fewer battery replacement requests.
Effective May 16, 2025, David R. Wells ceased serving as Chief Financial Officer of Envoy Medical, Inc.
The Company’s Chief Executive Officer, Brent T. Lucas, will serve as principal financial officer on an interim basis until a successor Chief Financial Officer is appointed.
On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith’s resignation.
On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material